文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

局部枸橼酸抗凝与全身肝素抗凝在接受连续性肾脏替代治疗及静脉-动脉体外膜氧合患者中的比较:一项回顾性多中心研究

Comparison between regional citrate anticoagulation and systemic heparin anticoagulation in patients undergoing continuous renal replacement therapy and venoarterial extracorporeal membrane oxygenation: A retrospective multicentric study.
PubMed 文献 · Ann Intensive Care · 2026-01-16
一句话结论在VA-ECMO联合CRRT患者中,局部枸橼酸抗凝与较低滤器血栓风险相关(aHR 0.35),且不增加出血或严重代谢并发症。

这项回顾性多中心研究纳入2019年1月至2021年12月法国四个ICU中同时接受VA-ECMO和CRRT的253例成人患者,分析599次CRRT sessions(局部枸橼酸抗凝106次,普通肝素493次)。主要终点为因凝血导致的非计划回路终止(滤器血栓),局部枸橼酸抗凝组72小时累积发生率17.0%,低于普通肝素组的26.6%(p=0.033);校正凝血参数和CRRT部位后,局部枸橼酸抗凝与较低滤器血栓风险相关(aHR=0.35,95%CI 0.21-0.59,p<0.001)。两组中位滤器寿命无显著差异(47小时 vs 44小时,p=0.144),出血事件(33.3% vs 37.6%,p=0.417)和严重代谢并发症均无增加。作者认为局部枸橼酸抗凝在该高危人群中安全有效,支持其作为有前景的抗凝策略。

要点

  • VA-ECMO联合CRRT患者中,局部枸橼酸抗凝组72小时滤器血栓累积发生率17.0%,低于普通肝素组的26.6%(p=0.033)。
  • 校正凝血参数和CRRT部位后,局部枸橼酸抗凝与滤器血栓风险降低相关(aHR=0.35,95%CI 0.21-0.59,p<0.001)。
  • 两组中位滤器寿命无显著差异:局部枸橼酸抗凝组47小时(IQR 21-90)vs 普通肝素组44小时(IQR 20-72),p=0.144。
  • 局部枸橼酸抗凝未减少出血事件(33.3% vs 37.6%,p=0.417),也未增加严重代谢并发症发生率。
  • 作者认为局部枸橼酸抗凝在VA-ECMO联合CRRT患者中安全有效,支持其作为有前景的抗凝策略。

适用人群与场景

  • 2019年1月至2021年12月法国四个ICU中同时接受VA-ECMO和CRRT的成人患者。

研究设计与关键结果

  • 回顾性多中心研究,纳入253例患者(77.9%男性,中位年龄61岁),分析599次CRRT sessions(局部枸橼酸抗凝106次,普通肝素493次)。
  • 主要终点为因凝血导致的非计划回路终止(滤器血栓),72小时累积发生率局部枸橼酸抗凝组17.0%(95%CI 10.5-24.8%)vs 普通肝素组26.6%(95%CI 22.8-30.5%),p=0.033。
  • 校正凝血参数和CRRT部位后,局部枸橼酸抗凝与滤器血栓风险降低相关(aHR=0.35,95%CI 0.21-0.59,p<0.001)。
  • 中位滤器寿命两组无显著差异:局部枸橼酸抗凝组47小时(IQR 21-90)vs 普通肝素组44小时(IQR 20-72),p=0.144。
  • 出血事件局部枸橼酸抗凝组33.3% vs 普通肝素组37.6%,p=0.417;局部枸橼酸抗凝未增加严重代谢并发症发生率。

证据类型、等级与局限

  • 证据类型:回顾性多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在VA-ECMO联合CRRT患者中,局部枸橼酸抗凝安全有效,与较低滤器血栓风险相关,且不增加出血或严重代谢并发症,支持其作为有前景的抗凝策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Regional citrate anticoagulation (RCA) is the recommended first-line strategy for continuous renal replacement therapy (CRRT) circuits. Acute kidney injury is common in patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO), and CRRT is frequently required. However, the use of RCA in this setting remains debated due to concerns about metabolic complications and limited evidence. This study aimed to compare the efficacy and safety of RCA versus unfractionated heparin (UFH) anticoagulation in this high-risk population.

MATERIALS AND METHODS: In this retrospective multicentric study, we included adult patients receiving simultaneous VA-ECMO and CRRT between January 2019 and December 2021 in four French intensive care units. The primary outcome was CRRT filter thrombosis, defined as unplanned circuit cessation due to clotting. Filter lifespan, defined as the time from CRRT initiation to cessation for any reason, was recorded as a secondary outcome. Additional secondary outcomes included bleeding events, transfusion requirements, coagulation parameters, and metabolic complications. Association of CRRT filter thrombosis with anticoagulation modality was assessed using a Fine-Gray regression model accounting for competing events, and adjusted for coagulation parameters and CRRT site. Missing data were handled using multiple imputation.

RESULTS: Among the 253 patients included (77.9% male, median age 61 years), 599 CRRT sessions were analyzed (RCA: 106; UFH: 493). Median filter lifespan did not differ significantly between groups (RCA: 47 [IQR 21-90] vs UFH: 44 [IQR 20-72] hours, p = 0.144). The estimated cumulative incidence of filter thrombosis at 72 h was 17.0% (95% CI, 10.5-24.8%) in the RCA group versus 26.6% (95% CI, 22.8-30.5%) in the UFH group; p = 0.033. RCA was associated with a significantly lower risk of filter thrombosis compared to UFH (aHR = 0.35 (95% CI, 0.21-0.59; p < 0.001)), after adjustment for coagulation parameters and CRRT site. RCA was not associated with decreased bleeding events (33.3% vs 37.6%, p = 0.417) and did not increase the incidence of severe metabolic complications.

CONCLUSION: In patients receiving VA-ECMO and CRRT, RCA was safe and effective. RCA was associated with a significantly lower risk of filter thrombosis, despite similar median filter lifespan, without increasing bleeding or severe metabolic complications. These findings support the use of RCA as a promising anticoagulation strategy in this high-risk population.

SPECIALTY: Critical Care.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Hirwe A, Omar E, Guinot PG, et al. Comparison between regional citrate anticoagulation and systemic heparin anticoagulation in patients undergoing continuous renal replacement therapy and venoarterial extracorporeal membrane oxygenation: A retrospective multicentric study. Ann Intensive Care. 2026. PMID: 41788497. doi:10.1016/j.aicoj.2025.100013

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。